Novavax Public Company

Formerly called Isconova, Novavax, Inc. is a public, clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, it produces vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Novavax's vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis. fThe company's product pipeline targets a variety of infectious diseases, with clinical vaccine candidates for respiratory syncytial virus (RSV), seasonal influenza and Ebola virus (EBOV) and a preclinical program for a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.